Valuation: Sybleu Inc.

Market Cap 531K 461K 428K 395K 744K 50.66M 757K 5.07M 1.98M 25.16M 1.99M 1.95M 84.62M P/E 2022 *
-
P/E 2023 -16.6x
Enterprise Value 1M 872K 810K 747K 1.41M 95.89M 1.43M 9.59M 3.76M 47.62M 3.77M 3.69M 160M EV / Sales 2022 *
-
EV / Sales 2023 298,725,376x
Free-Float
92.39%
Yield 2022 *
-
Yield 2023 -
3 years 0.01
Extreme 0.011
0.15
5 years 0.01
Extreme 0.011
0.29
10 years 0.01
Extreme 0.011
0.29
Manager TitleAgeSince
Chief Executive Officer - 12/04/2024
President - 12/04/2024
Corporate Secretary - 12/04/2024
Director TitleAgeSince
Director/Board Member - 12/04/2024
Chairman - 12/04/2024
Director/Board Member - 12/04/2024
Change 5-day change 1-year change 3-year change Capi.($)
+9.13%-.--%-.--%-44.94% 584K
-0.62%-1.34%+65.54%+21.26% 321B
+0.42%+2.87%+29.78%-10.42% 71.5B
-2.07%-0.27%+36.25%+90.20% 9.88B
-3.60%-2.43%-1.64%-5.95% 8.7B
+2.65%+1.04%-23.09%-5.02% 4.25B
+5.26%+5.41%-38.54%+12.12% 3.86B
-3.86%-8.18%-12.14%-2.26% 3.47B
-2.57%-2.55%+28.26%+46.69% 2.65B
-0.68%+4.52%-4.75%-5.33% 2.23B
Average +0.39%+1.15%+7.97%+9.63% 42.71B
Weighted average by Cap. -0.65%+4.46%+54.46%+16.48%

Financials

2022 2023
Net sales 0.01 0.01 0.01 0.01 0.02 1.12 0.02 0.11 0.04 0.55 0.04 0.04 1.87 0.01 0.01 0.01 0.01 0.02 1.12 0.02 0.11 0.04 0.55 0.04 0.04 1.86
Net income -245K -213K -198K -183K -344K -23.42M -350K -2.34M -917K -11.63M -921K -901K -39.12M -180K -157K -145K -134K -253K -17.21M -257K -1.72M -674K -8.55M -677K -662K -28.75M
Net Debt 73.15K 63.54K 59K 54.41K 102K 6.98M 104K 699K 274K 3.47M 275K 269K 11.66M 474K 411K 382K 352K 664K 45.22M 676K 4.52M 1.77M 22.46M 1.78M 1.74M 75.53M
Logo Sybleu Inc.
SYBLEU Inc. is engaged in the acquisition, licensing and development of medical and veterinary applications. The Company is focused on developing therapies for human and animal health, medical devices, and clinical diagnostics. The Company is also developing drugs for treating cancer in companion animals and examining the role of artificial intelligence and machine learning in clinical diagnostics. It is also involved in the development of disposable medical devices. The Company has completed Phase I and or Phase II clinical trials, after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.
Employees
-
  1. Stock Market
  2. Stocks
  3. SYBE Stock